Department of Urology, Wuhan Integrated TCM & Western Medicine Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No.1 Hospital, Wuhan, China.
BMC Nephrol. 2024 May 10;25(1):161. doi: 10.1186/s12882-024-03590-2.
Previous observational studies have reported that systemic inflammatory regulators are related to the development of chronic kidney disease (CKD); however, whether these associations are causal remains unclear. The current study aimed to investigate the potential causal relationships between systemic inflammatory regulators and CKD and kidney function.
We performed bidirectional two-sample Mendelian randomization (MR) analyses to infer the underlying causal associations between 41 systemic inflammatory regulators and CKD and kidney function. The inverse-variance weighting (IVW) test was used as the primary analysis method. In addition, sensitivity analyses were executed via the Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test and the weighted median test.
The findings revealed 12 suggestive associations between 11 genetically predicted systemic inflammatory regulators and CKD or kidney function in the forward analyses, including 4 for CKD, 3 for blood urea nitrogen (BUN), 4 for eGFRcrea and 1 for eGFRcys. In the other direction, we identified 6 significant causal associations, including CKD with granulocyte-colony stimulating factor (GCSF) (IVW β = 0.145; 95% CI, 0.042 to 0.248; P = 0.006), CKD with stem cell factor (SCF) (IVW β = 0.228; 95% CI, 0.133 to 0.323; P = 2.40 × 10), eGFRcrea with SCF (IVW β =-2.90; 95% CI, -3.934 to -1.867; P = 3.76 × 10), eGFRcys with GCSF (IVW β =-1.382; 95% CI, -2.404 to -0.361; P = 0.008), eGFRcys with interferon gamma (IFNg) (IVW β =-1.339; 95% CI, -2.313 to -0.366; P = 0.007) and eGFRcys with vascular endothelial growth factor (VEGF) (IVW β =-1.709; 95% CI, -2.720 to -0.699; P = 9.13 × 10).
Our findings support causal links between systemic inflammatory regulators and CKD or kidney function both in the forward and reverse MR analyses.
先前的观察性研究报告称,系统性炎症调节剂与慢性肾脏病(CKD)的发生发展有关;然而,这些关联是否具有因果关系尚不清楚。本研究旨在探讨系统性炎症调节剂与 CKD 和肾功能之间潜在的因果关系。
我们进行了双向两样本 Mendelian 随机化(MR)分析,以推断 41 种系统性炎症调节剂与 CKD 和肾功能之间的潜在因果关系。采用逆方差加权(IVW)检验作为主要分析方法。此外,还通过 Mendelian 随机化多效残余总和和异常值(MR-PRESSO)检验和加权中位数检验进行了敏感性分析。
在前向分析中,我们发现 11 种遗传预测的系统性炎症调节剂与 CKD 或肾功能之间存在 12 个提示性关联,其中包括 4 个与 CKD 相关,3 个与血尿素氮(BUN)相关,4 个与 eGFRcrea 相关,1 个与 eGFRcys 相关。在另一个方向上,我们确定了 6 个具有统计学意义的因果关联,包括 CKD 与粒细胞集落刺激因子(GCSF)(IVW β=0.145;95%CI,0.042 至 0.248;P=0.006)、CKD 与干细胞因子(SCF)(IVW β=0.228;95%CI,0.133 至 0.323;P=2.40×10)、eGFRcrea 与 SCF(IVW β=-2.90;95%CI,-3.934 至 -1.867;P=3.76×10)、eGFRcys 与 GCSF(IVW β=-1.382;95%CI,-2.404 至 -0.361;P=0.008)、eGFRcys 与干扰素γ(IFNg)(IVW β=-1.339;95%CI,-2.313 至 -0.366;P=0.007)和 eGFRcys 与血管内皮生长因子(VEGF)(IVW β=-1.709;95%CI,-2.720 至 -0.699;P=9.13×10)之间存在因果关系。
我们的研究结果支持系统性炎症调节剂与 CKD 或肾功能之间的因果关系,无论是在正向还是反向 Mendelian 随机化分析中。